Pink Sheet: global policy and regulatory coverage
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
By Mary Jo Laffler 11 Apr 2022
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Listen to speakers: Dominique Fontanilla , Senior Analyst; Mary Jo Laffler, Head of Commercial Content; and Steve Muntner, Head of Deals Intelligence explore:
Pink Sheet: global policy and regulatory coverage
By Mary Jo Laffler 11 Apr 2022
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Scrip: industry news and insights
By Mary Jo Laffler 22 Dec 2021
The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects...
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: